REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
REGENXBIO (Nasdaq: RGNX) will host a conference call on Thursday, March 5, 2026 at 8:00 a.m. ET to discuss fourth-quarter and full-year results for the period ended December 31, 2025, and operational highlights.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
REGENXBIO (Nasdaq: RGNX) will host a conference call on Thursday, March 5, 2026 at 8:00 a.m. ET to discuss fourth-quarter and full-year results for the period ended December 31, 2025, and operational highlights.
Investors can register for the webcast, analysts can request Q&A access, and a replay will be posted about two hours after the call.
Details
News Market Reaction – RGNX
On Feb 25, the day this news came out, RGNX closed 5.57% above the previous close.
Data tracked by StockTitan Argus for the Feb 25 session.
Key Figures
- Conference date
- March 5, 2026
- Scheduled call to discuss Q4 and full-year 2025 results
- Start time
- 8:00 a.m. ET
- Earnings and operational highlights conference call
- Fiscal year end
- December 31, 2025
- Period covered by Q4 and full-year results
- Replay availability
- Approximately two hours
- Delay before webcast replay is posted to investor website
- Early join time
- 15 minutes
- Recommended time for participants to join before call start
Previous Conferences,earnings Reports
-
Scheduled Q3 2025 earnings and operational highlights conference call.
-
Announced Q2 2025 results call with webcast and analyst Q&A details.
-
Set date for Q1 2025 financial results and operational update call.
-
Scheduled call for Q4 and full-year 2024 results and updates.
-
Announced Q3 2024 financial results and highlights conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-march-5-to-discuss-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights-302696540.html
SOURCE REGENXBIO Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.